InMed Pharmaceuticals Inc. (INM) Tops Q1 EPS by 390c

InMed Pharmaceuticals Inc. (NASDAQ: INM) reported Q1 EPS of ($0.60), $3.90 better than the analyst estimate of ($4.50). Revenue for the quarter came in at $1.03 million versus the consensus estimate of $700 thousand.

For earnings history and earnings-related data on InMed Pharmaceuticals Inc. (INM) click here.

You May Also Be Interested In

• Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
• Knowles (KN) Tops Q2 EPS by 2c, Offers Guidance
• Manhattan Bridge Capital (LOAN) Misses Q2 EPS by 1c